Published in Int J Cancer on October 15, 2006
Posttranscriptional regulation of cancer traits by HuR. Wiley Interdiscip Rev RNA (2010) 2.59
HuR function in disease. Front Biosci (Landmark Ed) (2012) 1.86
HuR cytoplasmic expression is associated with increased cyclin A expression and poor outcome with upper urinary tract urothelial carcinoma. BMC Cancer (2012) 0.92
Knocking-down cyclin A(2) by siRNA suppresses apoptosis and switches differentiation pathways in K562 cells upon administration with doxorubicin. PLoS One (2009) 0.90
Differences in protein expression and gene amplification of cyclins between colon and rectal adenocarcinomas. Gastroenterol Res Pract (2009) 0.87
Cyclin A2 confers cisplatin resistance to endometrial carcinoma cells via up-regulation of an Akt-binding protein, periplakin. J Cell Mol Med (2010) 0.81
Cathepsin L suppression increases the radiosensitivity of human glioma U251 cells via G2/M cell cycle arrest and DNA damage. Acta Pharmacol Sin (2015) 0.79
JAZ mediates G1 cell cycle arrest by interacting with and inhibiting E2F1. Cell Cycle (2011) 0.78
Analysis of cell cycle-related proteins in gastric intramucosal differentiated-type cancers based on mucin phenotypes: a novel hypothesis of early gastric carcinogenesis based on mucin phenotype. BMC Gastroenterol (2010) 0.78
Increased cyclin T1 expression as a favorable prognostic factor in treating gastric adenocarcinoma. Oncol Lett (2015) 0.75
Radical prostatectomy versus watchful waiting in early prostate cancer. N Engl J Med (2005) 16.35
Radical prostatectomy versus watchful waiting in early prostate cancer. N Engl J Med (2011) 13.30
Radical prostatectomy or watchful waiting in early prostate cancer. N Engl J Med (2014) 10.06
Radical prostatectomy versus watchful waiting in localized prostate cancer: the Scandinavian prostate cancer group-4 randomized trial. J Natl Cancer Inst (2008) 8.62
The common colorectal cancer predisposition SNP rs6983267 at chromosome 8q24 confers potential to enhanced Wnt signaling. Nat Genet (2009) 5.65
Prognostic significance of elevated cyclooxygenase-2 expression in breast cancer. Cancer Res (2002) 3.70
Dual role of FoxA1 in androgen receptor binding to chromatin, androgen signalling and prostate cancer. EMBO J (2011) 2.55
National Academy of Clinical Biochemistry laboratory medicine practice guidelines for use of tumor markers in testicular, prostate, colorectal, breast, and ovarian cancers. Clin Chem (2008) 2.44
Prognostic significance of elevated cyclooxygenase 2 expression in patients with adenocarcinoma of the esophagus. Gastroenterology (2002) 2.19
Cytoplasmic HuR expression is a prognostic factor in invasive ductal breast carcinoma. Cancer Res (2005) 1.94
Transcription factor PROX1 induces colon cancer progression by promoting the transition from benign to highly dysplastic phenotype. Cancer Cell (2008) 1.82
MYC-dependent regulation and prognostic role of CIP2A in gastric cancer. J Natl Cancer Inst (2009) 1.80
High frequency of BRAF V600E mutations in ameloblastoma. J Pathol (2014) 1.79
Oncolytic adenovirus coding for granulocyte macrophage colony-stimulating factor induces antitumoral immunity in cancer patients. Cancer Res (2010) 1.69
Guidelines for the management of gastroenteropancreatic neuroendocrine tumours (including bronchopulmonary and thymic neoplasms). Part I-general overview. Acta Oncol (2004) 1.62
Cytoplasmic HuR expression correlates with poor outcome and with cyclooxygenase 2 expression in serous ovarian carcinoma. Cancer Res (2003) 1.50
Targets of gene amplification and overexpression at 17q in gastric cancer. Cancer Res (2002) 1.46
LKB1 signaling in mesenchymal cells required for suppression of gastrointestinal polyposis. Nat Genet (2008) 1.46
Breast cancer patients with p53 Pro72 homozygous genotype have a poorer survival. Clin Cancer Res (2005) 1.46
Breast cancer biological subtypes and protein expression predict for the preferential distant metastasis sites: a nationwide cohort study. Breast Cancer Res (2011) 1.42
Prognostic role of HuR in hereditary breast cancer. Clin Cancer Res (2007) 1.41
CIP2A expression is increased in prostate cancer. J Exp Clin Cancer Res (2010) 1.39
Intussusception and spontaneous amputation of the esophagus. J Thorac Cardiovasc Surg (2002) 1.38
Cyclooxygenase-2 expression during carcinogenesis in the human stomach. J Pathol (2002) 1.35
Cyclooxygenase-2 is an independent prognostic factor in gastric cancer and its expression is regulated by the messenger RNA stability factor HuR. Clin Cancer Res (2005) 1.34
The novel WHO 2010 classification for gastrointestinal neuroendocrine tumours correlates well with the metastatic potential of rectal neuroendocrine tumours. Neuroendocrinology (2012) 1.29
Early-onset gastric cancers have a different molecular expression profile than conventional gastric cancers. Mod Pathol (2006) 1.27
Guidelines for the management of gastroenteropancreatic neuroendocrine tumours (including bronchopulmonary and thymic neoplasms). Part II-specific NE tumour types. Acta Oncol (2004) 1.23
Identification of tumor epithelium and stroma in tissue microarrays using texture analysis. Diagn Pathol (2012) 1.23
15-hydroxyprostaglandin dehydrogenase is down-regulated in gastric cancer. Clin Cancer Res (2009) 1.23
Association between cyclooxygenase-2 expression in atypical hyperplasia and risk of breast cancer. J Natl Cancer Inst (2008) 1.22
Unregulated smooth-muscle myosin in human intestinal neoplasia. Proc Natl Acad Sci U S A (2008) 1.20
Use of faecal markers in screening for colorectal neoplasia: a European group on tumor markers position paper. Int J Cancer (2011) 1.19
Prognostic value of syndecan-1 expression in breast cancer. Oncology (2004) 1.16
Ski-related novel protein N (SnoN), a negative controller of transforming growth factor-beta signaling, is a prognostic marker in estrogen receptor-positive breast carcinomas. Cancer Res (2003) 1.14
Gastric cancer: basic aspects. Helicobacter (2012) 1.11
Elevated cyclooxygenase-2 expression is associated with altered expression of p53 and SMAD4, amplification of HER-2/neu, and poor outcome in serous ovarian carcinoma. Clin Cancer Res (2004) 1.11
BMPR1A mutations in hereditary nonpolyposis colorectal cancer without mismatch repair deficiency. Gastroenterology (2011) 1.10
Serum HCG beta, CA 72-4 and CEA are independent prognostic factors in colorectal cancer. Int J Cancer (2002) 1.09
Candidate driver genes in microsatellite-unstable colorectal cancer. Int J Cancer (2011) 1.08
Gastric cancer: basic aspects. Helicobacter (2011) 1.08
Integrated gene copy number and expression microarray analysis of gastric cancer highlights potential target genes. Int J Cancer (2008) 1.07
Phospholipase PLA2G7, associated with aggressive prostate cancer, promotes prostate cancer cell migration and invasion and is inhibited by statins. Oncotarget (2011) 1.07
Antiangiogenic arming of an oncolytic vaccinia virus enhances antitumor efficacy in renal cell cancer models. J Virol (2009) 1.06
Association of cyclooxygenase-2 and matrix metalloproteinase-2 expression in human breast cancer. Breast Cancer Res Treat (2005) 1.06
Cyclooxygenase-2 and gastric carcinogenesis. APMIS (2003) 1.06
Gene expression analysis identifies over-expression of CXCL1, SPARC, SPP1, and SULF1 in gastric cancer. Genes Chromosomes Cancer (2010) 1.06
Serum HCG beta and CA 72-4 are stronger prognostic factors than CEA, CA 19-9 and CA 242 in pancreatic cancer. Oncology (2004) 1.06
Expression of microsomal prostaglandin E synthase-1 in intestinal type gastric adenocarcinoma and in gastric cancer cell lines. Int J Cancer (2003) 1.05
Tissue-specific promoters active in CD44+CD24-/low breast cancer cells. Cancer Res (2008) 1.05
Increased C-reactive protein implies a poorer stage-specific prognosis in colon cancer. Acta Oncol (2013) 1.03
Toward a Molecular Classification of Colorectal Cancer: The Role of BRAF. Front Oncol (2013) 1.02
Expression of cyclooxygenase-2 is regulated by glycogen synthase kinase-3beta in gastric cancer cells. J Biol Chem (2005) 1.02
CEA, CA 242, CA 19-9, CA 72-4 and hCGbeta in the diagnosis of recurrent colorectal cancer. Tumour Biol (2005) 1.01
Genetic and epigenetic alteration in gastric carcinogenesis. Helicobacter (2010) 1.01
COX-2 is associated with proliferation and apoptosis markers and serves as an independent prognostic factor in gastric cancer. Tumour Biol (2009) 1.00
Podocalyxin is a marker of poor prognosis in colorectal cancer. BMC Cancer (2014) 0.99
Xanthine oxidoreductase - clinical significance in colorectal cancer and in vitro expression of the protein in human colon cancer cells. Eur J Cancer (2008) 0.99
Syndecan-1 expression--a novel prognostic marker in pancreatic cancer. Oncology (2005) 0.99
Coamplified and overexpressed genes at ERBB2 locus in gastric cancer. Int J Cancer (2004) 0.98
Analysis of the human cancer glycome identifies a novel group of tumor-associated N-acetylglucosamine glycan antigens. Cancer Res (2009) 0.97
Tenascin-C expression correlates with prognosis in gastric cancer. Oncology (2003) 0.97
CIP2A overexpression is associated with c-Myc expression in colorectal cancer. Cancer Biol Ther (2012) 0.97
Bmi-1, c-myc, and Snail expression in primary breast cancers and their metastases--elevated Bmi-1 expression in late breast cancer relapses. Virchows Arch (2011) 0.96
BRAF mutation in sporadic colorectal cancer and Lynch syndrome. Virchows Arch (2013) 0.96
Inflammation and disease duration have a cumulative effect on the risk of dysplasia and carcinoma in IBD: a case-control observational study based on registry data. Int J Cancer (2013) 0.96
Relative concentrations of hK2/PSA mRNA in benign and malignant prostatic tissue. Prostate (2005) 0.96
Systemic adenoviral gene delivery to orthotopic murine breast tumors with ablation of coagulation factors, thrombocytes and Kupffer cells. J Gene Med (2009) 0.96
Expression of trypsinogen-1, trypsinogen-2, and tumor-associated trypsin inhibitor in ovarian cancer: prognostic study on tissue and serum. Clin Cancer Res (2004) 0.95
Genome-wide gene copy number and expression analysis of primary gastric tumors and gastric cancer cell lines. BMC Cancer (2010) 0.95
MMP-7 overexpression is an independent prognostic marker in gastric cancer. Tumour Biol (2010) 0.95